Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-31
2010-02-16
Yaen, Christopher H (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07662378
ABSTRACT:
The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.
REFERENCES:
patent: 5843708 (1998-12-01), Hardman et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 7011812 (2006-03-01), Griffiths et al.
patent: 7238785 (2007-07-01), Govindan et al.
Nowak et al. “Induction of Tumor Cell Apoptosis in Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells” J. Immunol. 170:4905-13 (2003).
Ray et al. “Apoptosis Induction of Prostate Cancer Cells and Xenografts by Combined Treatment with Apo2 Ligand/ Tumor Necrosis Factor-related Apoptosis-inducing Ligand and CPT-11” Can. Res. 63:4713-23 (2003).
Rigas et al. “Selective Induction of Colon Cancer Cell Apoptosis by 5-Flourouracil in Humans” Abstract, Cancer Invest. 20:657-65 (2002).
Mani et al. “Novel Combinations with Oxaliplatin” Abstract, Oncol. 14:52-8 (2000).
Groninger et al. “Vincristine Induced Apoptosis in Acute Lymphoblastic Leukaemia Cells: A Mitochondrial Controlled Pathway Regulated by Reactive Oxygen Species?” Abstract, Int. J. Oncol. 21:1339-45(2002).
Tsang et al. “Reactive Oxygen Species Mediate Doxorubicin Induced p53-Independent Apoptosis” Life Sci. 73:2047-58 (2003).
Shibuya et al. “Induction of Apoptosis and/or Necrosis Following Exposure to Antitumour Agents in a Melanoma Cell Line, Probably Through Modulation of BcI-2 Family Proteins” Abstract, Melanoma Res. 13:457-64 (2003).
Ueno et al. “SN-38 Induces Cell Cycle Arrest and Apoptosis in Human Testicular Cancer” Eur. Urol. 42:390-7 (2002).
Simoes-Wust et al. “Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide” Abstract, Breast Cancer Res. 76:157-66 (2002).
Stein et al. “Combining Radioimmunotherapy and Chemotherapy for Treatment of Medullary Thyroid Carcinoma” Cancer 94:51-61 (2002).
Sharkey et al. “Murine Monoclonal Antibodies against Carcinoembryonic Antigen: Immunological, Pharmacokinetic, and Targeting Properties in Humans” Cancer Res., 50:2823-2831 (1990).
Blumenthal et al. “Comparison of Equitoxic Radioimmunotherapy and Chemotherapy in the Treatment of Human Colonic Cancer Xenografts” Cancer Res., 54:142-151 (1994).
Perez et al. “A Multivalent Recombinant Antibody Fragment Specific for Carcinoembryonic Antigen” Biotechnol. Appl. Biochem. 43:39-48 (2006).
Wong et al. “A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies” Clin. Can. Res. 6:3855-3863 (2000).
Wong et al. “A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer” Clin. Can. Res. 9:5842-5852 (2003).
Wong et al. “Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer” Clin. Can. Res. 10:5014-5021 (2004).
Begent et al. “Clinical Evidence of Efficient Tumor Targeting Based on Single-Chain Fv Antibody Selected from a Combinatorial Library” Nat. Med. 2:979-984 (1996).
Mayer et al. “Radioimmunoguided Surgery in Colorectal Cancer Using a Genetically Engineered Anti-CEA Single-Chain Fv Antibody” Clin. Can. Res. 6:1711-1719 (2000).
Beckman et al. “Antibody Constructs in Cancer Therapy” Cancer 109:170-179 (2007).
Dennis, C. “Off by a Whisker” Nature 442:739-741 (2006).
Pascalis et al. “Grafting of “Abbreviated” Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenetic Humanized Monoclonal Antibody” Journal of Immunology 169:3076-3084 (2002).
Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis” J. Mol. Biol. 320:415-428 (2002).
Wu et al. “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues” J. Mol. Biol. 294:151-162 (1999).
Neumaier et al. “Cloning of the Genes for T84.66, an Antibody that has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse T84.66 Genes in Myeloma and Chinese Hamster Ovary Cells” Can. Res. 50:2128-2134 (1990).
Voskoglou-Nomikos et al. “Clinical Predictive Value of the in Vitro Cell Line, Human Xenograft, and Mouse Allograft Preclinical Cancer Models” Clin. Can. Res. 9:4227-4239 (2003).
Nap et al. “Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen” Can. Res. 52:2329-2339 (1992).
Goldenberg David M.
Hansen Hans J.
Immunomedics Inc.
Nakashima Richard A.
Yaen Christopher H
LandOfFree
Antibody therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169570